RT Journal Article
SR Electronic
T1 Scalable and Resilient SARS-CoV-2 testing in an Academic Centre
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.19.20071373
DO 10.1101/2020.04.19.20071373
A1 ,
A1 Aitken, J
A1 Ambrose, K
A1 Barrell, S
A1 Beale, R
A1 Bineva-Todd, G
A1 Biswas, D
A1 Byrne, R
A1 Caidan, S
A1 Cherepanov, P
A1 Churchward, L
A1 Clark, G
A1 Crawford, M
A1 Cubitt, L
A1 Dearing, V
A1 Earl, C
A1 Edwards, A
A1 Ekin, C
A1 Fidanis, E
A1 Gaiba, A
A1 Gamblin, S
A1 Gandhi, S
A1 Goldman, J
A1 Goldstone, R
A1 Grant, PR
A1 Greco, M
A1 Heaney, J
A1 Hindmarsh, S
A1 Houlihan, C F
A1 Howell, M
A1 Hubank, M
A1 Hughes, D
A1 Instrell, R
A1 Jackson, D
A1 Jamal-Hanjani, M
A1 Jiang, M
A1 Johnson, M
A1 Jones, L
A1 Kanu, N
A1 Kassiotis, G
A1 Kirk, S
A1 Kjaer, S
A1 Levett, A
A1 Levett, L
A1 Levi, M
A1 Lu, WT
A1 MacRae, J I
A1 Matthews, J
A1 McCoy, L
A1 Moore, C
A1 Moore, D
A1 Nastouli, E
A1 Nicod, J
A1 Nightingale, L
A1 Olsen, J
A1 O’Reilly, N
A1 Pabari, A
A1 Papayannopoulos, V
A1 Patel, N
A1 Peat, N
A1 Pollitt, M
A1 Ratcliffe, P
A1 Reis e, Sousa C
A1 Rosa, A
A1 Rosenthal, R
A1 Roustan, C
A1 Rowan, A
A1 Shin, GY
A1 Snell, DM
A1 Song, OR
A1 Spyer, M
A1 Strange, A
A1 Swanton, C
A1 Turner, JMA
A1 Turner, M
A1 Wack, A
A1 Walker, P A
A1 Ward, S
A1 Wong, WK
A1 Wright, J
A1 Wu, M
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.04.19.20071373.abstract
AB The emergence of the novel coronavirus SARS-CoV-2 has led to a pandemic infecting more than two million people worldwide in less than four months, posing a major threat to healthcare systems. This is compounded by the shortage of available tests causing numerous healthcare workers to unnecessarily self-isolate. We provide a roadmap instructing how a research institute can be repurposed in the midst of this crisis, in collaboration with partner hospitals and an established diagnostic laboratory, harnessing existing expertise in virus handling, robotics, PCR, and data science to derive a rapid, high throughput diagnostic testing pipeline for detecting SARS-CoV-2 in patients with suspected COVID-19. The pipeline is used to detect SARS-CoV-2 from combined nose-throat swabs and endotracheal secretions/ bronchoalveolar lavage fluid. Notably, it relies on a series of in-house buffers for virus inactivation and the extraction of viral RNA, thereby reducing the dependency on commercial suppliers at times of global shortage. We use a commercial RT-PCR assay, from BGI, and results are reported with a bespoke online web application that integrates with the healthcare digital system. This strategy facilitates the remote reporting of thousands of samples a day with a turnaround time of under 24 hours, universally applicable to laboratories worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Francis Crick Institute that receives its core funding from Cancer Research UK (FC001169, FC001078), the UK Medical Research Council (FC001169, FC001078), and the Wellcome Trust (FC001169, FC001078). C.S. is Royal Society Napier Research Professor and is also funded by the Breast Cancer Research Foundation (BCRF). E.N. receives research funding from the NIHR, MRC, GSK and H2020. S.Gandhi is an MRC Senior Clinical Fellow. The authors wish to thank Heather Ringrose for support with the Hamilton liquid handling workstation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExtended protocols are included in the Supplementary Methods